274 related articles for article (PubMed ID: 15353478)
21. Immunotherapy targeting 4-1BB and its ligand.
Vinay DS; Kwon BS
Int J Hematol; 2006 Jan; 83(1):23-8. PubMed ID: 16443548
[TBL] [Abstract][Full Text] [Related]
22. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.
Lee HW; Park SJ; Choi BK; Kim HH; Nam KO; Kwon BS
J Immunol; 2002 Nov; 169(9):4882-8. PubMed ID: 12391199
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells.
Kim YJ; Broxmeyer HE
J Hematother Stem Cell Res; 2001 Aug; 10(4):441-9. PubMed ID: 11522228
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation.
Sun Y; Blink SE; Liu W; Lee Y; Chen B; Solway J; Weinstock J; Chen L; Fu YX
J Immunol; 2006 Jul; 177(2):814-21. PubMed ID: 16818735
[TBL] [Abstract][Full Text] [Related]
25. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
26. 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells.
Laderach D; Movassagh M; Johnson A; Mittler RS; Galy A
Int Immunol; 2002 Oct; 14(10):1155-67. PubMed ID: 12356681
[TBL] [Abstract][Full Text] [Related]
27. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
28. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
29. 4-1BB (CD137) differentially regulates murine in vivo protein- and polysaccharide-specific immunoglobulin isotype responses to Streptococcus pneumoniae.
Wu ZQ; Khan AQ; Shen Y; Wolcott KM; Dawicki W; Watts TH; Mittler RS; Snapper CM
Infect Immun; 2003 Jan; 71(1):196-204. PubMed ID: 12496166
[TBL] [Abstract][Full Text] [Related]
30. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.
Bertram EM; Dawicki W; Sedgmen B; Bramson JL; Lynch DH; Watts TH
J Immunol; 2004 Jan; 172(2):981-8. PubMed ID: 14707071
[TBL] [Abstract][Full Text] [Related]
31. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity.
Cooper D; Bansal-Pakala P; Croft M
Eur J Immunol; 2002 Feb; 32(2):521-9. PubMed ID: 11828369
[TBL] [Abstract][Full Text] [Related]
32. Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice.
Fukushima A; Yamaguchi T; Ishida W; Fukata K; Mittler RS; Yagita H; Ueno H
J Immunol; 2005 Oct; 175(8):4897-903. PubMed ID: 16210591
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic potential of 4-1BB (CD137) in cancer.
Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
35. Differential clonal expansion of CD4 and CD8 T cells in response to 4-1BB ligation: contribution of 4-1BB during inflammatory responses.
Takahashi C; Mittler RS; Vella AT
Immunol Lett; 2001 Apr; 76(3):183-91. PubMed ID: 11306146
[TBL] [Abstract][Full Text] [Related]
36. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+ and CD8+ naïve human T-cells.
Gunnlaugsdottir B; Maggadottir SM; Ludviksson BR
Int Immunol; 2005 Jan; 17(1):35-44. PubMed ID: 15557315
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
Sabel MS; Conway TF; Chen FA; Bankert RB
J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
[TBL] [Abstract][Full Text] [Related]
39. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis.
Sun Y; Lin X; Chen HM; Wu Q; Subudhi SK; Chen L; Fu YX
J Immunol; 2002 Feb; 168(3):1457-65. PubMed ID: 11801689
[TBL] [Abstract][Full Text] [Related]
40. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
